Company Overview

RAMM Pharma Corp. is a pharmaceutical and cannabis-focused company operating at the intersection of regulated cannabis, pharmaceutical manufacturing, and healthcare distribution. The company’s core activities involve the production, commercialization, and distribution of cannabis-derived products and pharmaceutical-grade formulations, primarily for medical and scientific markets. RAMM operates within the pharmaceutical, medical cannabis, and healthcare distribution industries, with a strategic emphasis on regulated international markets rather than adult-use retail.

The company’s primary revenue drivers have historically included the sale and distribution of pharmaceutical products through licensed channels and the development of cannabis-derived medicines. RAMM has positioned itself as an early entrant into Latin American medical cannabis markets, particularly Uruguay, leveraging local regulatory approvals and infrastructure. Founded in 2014 and originally focused on pharmaceutical imports and distribution, RAMM later expanded into cannabis cultivation and extraction following regulatory changes, evolving into a vertically integrated operator with both pharmaceutical and cannabis assets.

Business Operations

RAMM conducts its operations through two principal business activities: pharmaceutical distribution and cannabis cultivation and processing. Its pharmaceutical operations have historically been conducted through RM Pharma, a licensed importer and distributor of pharmaceutical products to hospitals and pharmacies. This segment has provided established relationships with healthcare providers and regulatory authorities and has served as a foundational revenue base.

The cannabis-focused operations are primarily conducted through RAMM Pharma Uruguay, which holds licenses for cannabis cultivation, extraction, and research. The company controls cultivation assets, extraction facilities, and formulation capabilities designed to meet pharmaceutical-grade standards. Operations are concentrated in Uruguay, with limited commercial activity elsewhere, and revenue generation has been subject to regulatory timelines, licensing constraints, and market access approvals. Public disclosures indicate no material joint ventures with multinational pharmaceutical companies, and commercial scale remains limited relative to larger peers.

Strategic Position & Investments

RAMM’s strategic direction has centered on leveraging Uruguay’s federally regulated cannabis framework to develop pharmaceutical-grade cannabis products for export and research applications. Growth initiatives have included investment in cultivation infrastructure, extraction technology, and intellectual property related to cannabis formulations. The company has also emphasized regulatory compliance and pharmaceutical standards as a means of differentiating itself from consumer-oriented cannabis producers.

Notable investments have included capital expenditures into cultivation and processing facilities and the expansion of laboratory and research capabilities. RAMM has reported interests in developing cannabinoid-based therapeutics and participating in clinical research, although large-scale commercialization and late-stage clinical programs have not been conclusively demonstrated in public filings. Data inconclusive based on available public sources regarding the material impact of these initiatives on long-term revenue growth.

Geographic Footprint

RAMM’s operational footprint is primarily concentrated in Uruguay, which serves as the company’s main cultivation, processing, and research hub. Uruguay’s national cannabis regulatory framework has enabled RAMM to secure licenses that are difficult to obtain in many other jurisdictions, forming the backbone of its international strategy. The company’s headquarters and primary corporate administration have been reported in Canada, reflecting its public listing and corporate domicile.

Internationally, RAMM has indicated ambitions to access broader Latin American and international medical markets, but tangible operational presence outside Uruguay and Canada appears limited. Export activity and foreign market penetration remain subject to regulatory approvals and bilateral trade agreements, with no verified evidence of sustained large-scale international sales as of the latest public disclosures.

Leadership & Governance

RAMM is led by an executive team with experience in pharmaceuticals, healthcare logistics, and regulated cannabis markets. The leadership has consistently emphasized regulatory compliance, capital discipline, and long-term positioning in medical cannabis rather than rapid expansion into consumer markets. Corporate governance follows Canadian public company standards, with oversight by a board of directors and compliance with continuous disclosure obligations.

Key executives include:

• Howard Scher – Chief Executive Officer
• Paul Walsh – Chief Financial Officer
• Dr. Melania Dalla Costa – Chief Science Officer
• Rafael Peluffo – President, Uruguay Operations

Leadership communications have articulated a strategy focused on scientific credibility, pharmaceutical-grade production, and selective market participation, though execution has been influenced by capital availability and evolving regulatory environments.